Last updated: September 29, 2026
Ipilimumab, marketed by Bristol Myers Squibb as Yervoy, is a mature but commercially durable immuno-oncology biologic. Its standalone revenue has stabilized near $2 billion annually, while its strategic value is larger because it enables high-value combinations with nivolumab, marketed as Opdivo. U.S. biologic exclusivity expired in 2023, but patent protection and manufacturing complexity continue to delay biosimilar competition. The primary long-term risk is competitive displacement by PD-1 and PD-L1 therapies, not immediate generic substitution.
What is ipilimumab and how is Yervoy used?
Ipilimumab is a recombinant human monoclonal antibody that blocks CTLA-4, an immune checkpoint receptor. It increases T-cell activation and is used across multiple cancer indications, either alone or with nivolumab.
The U.S. Food and Drug Administration approved Yervoy in March 2011 for unresectable or metastatic melanoma. Subsequent approvals expanded its use into renal cell carcinoma, colorectal cancer with microsatellite instability or mismatch-repair deficiency, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, mesothelioma and other tumors, primarily in combination with nivolumab.[1]
Major FDA-approved commercial uses
| Indication |
Typical commercial role |
| Melanoma |
Monotherapy and combination therapy |
| Renal cell carcinoma |
Nivolumab plus ipilimumab |
| Non-small cell lung cancer |
Combination regimen in selected patients |
| Colorectal cancer |
MSI-high or dMMR disease |
| Hepatocellular carcinoma |
Nivolumab plus ipilimumab |
| Esophageal and gastroesophageal cancers |
Combination therapy |
| Pleural mesothelioma |
Nivolumab plus ipilimumab |
Ipilimumab has a distinct mechanism from PD-1 inhibitors. Its clinical use is constrained by immune-mediated adverse events, including colitis, hepatitis, hypophysitis, dermatitis and pneumonitis. These safety issues limit broad first-line use but preserve demand in high-response combination regimens.
How large is the ipilimumab market?
Yervoy generated approximately $2.1 billion in global revenue in 2023, according to Bristol Myers Squibb’s annual report. Revenue increased from approximately $1.3 billion in 2018 as combination use expanded across melanoma, renal cell carcinoma and lung cancer.[2]
Yervoy revenue trajectory
| Fiscal year |
Yervoy revenue, approximate |
| 2018 |
$1.3 billion |
| 2019 |
$1.5 billion |
| 2020 |
$1.9 billion |
| 2021 |
$1.9 billion |
| 2022 |
$2.1 billion |
| 2023 |
$2.1 billion |
The growth pattern changed after 2021. Earlier revenue expansion came from new indications and increased use with Opdivo. More recent performance reflects a mature product with stable demand, broader global access and continued use in combination regimens.
Yervoy represented roughly 4% to 5% of Bristol Myers Squibb’s 2023 revenue. That percentage understates its commercial importance because ipilimumab helps support Opdivo-based treatment protocols. A decline in ipilimumab availability could therefore affect both Yervoy revenue and the competitiveness of the broader Opdivo franchise.
What drives ipilimumab demand?
The most important demand driver is combination therapy with nivolumab. The two agents are frequently positioned as a dual-checkpoint regimen for patients who require deeper or more durable immune activation.
Combination economics
Combination treatment supports:
- Higher per-patient drug spending than monotherapy.
- Cross-selling within Bristol Myers Squibb’s oncology portfolio.
- Use in first-line and advanced disease settings.
- Greater clinical differentiation from single-agent PD-1 therapy.
- A wider commercial role for Yervoy despite its mature patent position.
The combination also creates a pricing and access challenge. Payers may restrict dual-checkpoint therapy because of higher cost, greater toxicity and the availability of less toxic PD-1 or PD-L1 monotherapy.
Competitive products
Ipilimumab competes indirectly with several checkpoint inhibitors:
| Product |
Company |
Target |
| Keytruda |
Merck & Co. |
PD-1 |
| Opdivo |
Bristol Myers Squibb |
PD-1 |
| Tecentriq |
Roche |
PD-L1 |
| Imfinzi |
AstraZeneca |
PD-L1 |
| Libtayo |
Regeneron and Sanofi |
PD-1 |
The most direct commercial comparison is between Yervoy-based combinations and PD-1 or PD-L1 monotherapy. Keytruda has stronger commercial scale and broader use in many tumor types. Yervoy retains value where CTLA-4 and PD-1 blockade produces better efficacy or where guidelines support dual-checkpoint treatment.
When does ipilimumab lose regulatory exclusivity?
Yervoy’s U.S. biologic reference-product exclusivity began with its March 25, 2011 approval. The 12-year period under the Biologics Price Competition and Innovation Act generally ended in March 2023.[3]
Regulatory exclusivity and patent protection are separate rights:
| Protection |
Approximate status |
| FDA reference-product biologic exclusivity |
Ended in March 2023 |
| Patent protection |
Extends beyond regulatory exclusivity |
| Biosimilar approval pathway |
Available after exclusivity expiration |
| Automatic generic substitution |
Not applicable to biologics in the traditional small-molecule sense |
The end of biologic exclusivity permits biosimilar applicants to rely on the reference product’s FDA data package under the abbreviated pathway. It does not eliminate patent litigation risk or guarantee immediate market entry.
What patents protect ipilimumab and Yervoy?
The core patent estate is based on anti-CTLA-4 antibodies, their sequences, therapeutic applications and related manufacturing or formulation claims. The principal foundational U.S. patent associated with ipilimumab is U.S. Patent No. 6,984,720, covering human CTLA-4 antibodies and related therapeutic concepts. Public patent records associate the underlying technology with Medarex, which Bristol Myers Squibb acquired in 2009.[4]
Representative patent categories
| Patent category |
Commercial purpose |
Expected risk profile |
| Anti-CTLA-4 antibody composition claims |
Protect ipilimumab or related antibody structures |
Core validity and scope questions |
| Method-of-use claims |
Protect cancer treatment using CTLA-4 blockade |
Indication-specific litigation risk |
| Combination claims |
Protect ipilimumab plus nivolumab treatment |
Potentially important for label-specific biosimilar use |
| Formulation claims |
Protect stability and injectable presentation |
Usually narrower than composition claims |
| Manufacturing claims |
Protect cell culture, purification or production methods |
Can increase biosimilar development cost |
The foundational patent has a listed term extending into the 2020s, with Orange Book and FDA patent records providing the controlling product-specific information.[5] Yervoy’s commercial protection therefore transitions from a high-value composition patent estate to narrower method, formulation and process barriers.
What is the Orange Book status of Yervoy?
Yervoy is listed in the FDA’s Orange Book as a prescription biological product with patent information associated with the approved product. The Orange Book is relevant to listed patents, but it does not capture every potential patent that could affect a biosimilar or follow-on biologic.
For biologics, the Purple Book and the BPCIA patent-exchange process are more relevant than the Hatch-Waxman framework used for small-molecule drugs. An ipilimumab biosimilar applicant would evaluate:
- The reference product’s FDA approval and exclusivity dates.
- Patent information supplied by Bristol Myers Squibb.
- Manufacturing and analytical comparability requirements.
- Interchangeability strategy.
- Indication-specific method-of-use claims.
- Potential state substitution rules.
Are there ipilimumab Paragraph IV challenges?
A traditional Paragraph IV challenge is a Hatch-Waxman mechanism for small-molecule drugs. It is not the standard pathway for a biosimilar to ipilimumab.
A biosimilar applicant would instead use the BPCIA framework, including patent-information exchanges and potential declaratory or infringement litigation. Publicly reported Yervoy-specific Paragraph IV litigation is not the principal competitive issue. The relevant exposure is biosimilar patent litigation involving composition, method-of-use, formulation or manufacturing claims.
What biosimilar risk exists for ipilimumab?
Biosimilar risk is material but likely gradual. Ipilimumab is a complex monoclonal antibody, and development requires extensive analytical characterization, comparative clinical evidence and a commercially viable manufacturing process.
Risk factors supporting delayed biosimilar entry
- Complex antibody production and purification.
- Need to demonstrate similarity across multiple quality attributes.
- High clinical and regulatory cost.
- Limited ability to substitute automatically at the pharmacy level.
- Dependence on combination regimens with nivolumab.
- Potential patent protection through the mid-2020s.
- Need to secure reimbursement and physician adoption.
Factors that increase biosimilar pressure
- Expiration of the 12-year U.S. biologic exclusivity period.
- Large annual Yervoy revenue base.
- High treatment costs.
- Mature clinical evidence.
- Availability of experienced oncology biosimilar manufacturers.
- Payer interest in reducing immune-oncology spending.
The first biosimilar entrant could target the highest-volume ipilimumab indications and compete through discounts rather than immediate full substitution. Uptake would likely be faster in hospital systems and integrated payer networks than in community oncology markets with established branded treatment pathways.
What patent litigation affects ipilimumab?
The main litigation risk is prospective rather than a history of extensive public Yervoy-specific challenges. Biosimilar applicants could face claims involving:
- Antibody sequence or structure.
- Use of ipilimumab in defined tumor types.
- Dosing schedules.
- Combination treatment with nivolumab.
- Pharmaceutical composition and stability.
- Cell-line or purification processes.
Method-of-use patents may have limited practical force when biosimilar labels omit protected indications. Bristol Myers Squibb could still pursue infringement if prescribing, reimbursement or product materials encourage use for a patented indication.
No broad public record of a settled, market-defining Yervoy biosimilar dispute had emerged through 2024. The absence of a major settlement does not remove future litigation exposure.
How strong is the ipilimumab patent estate?
The estate is commercially moderate rather than exceptionally strong.
Strengths
- Long clinical history and substantial regulatory documentation.
- A validated antibody with multiple approved uses.
- Combination-treatment claims linked to Opdivo.
- Manufacturing complexity that raises biosimilar barriers.
- Continued clinical value in tumors where dual checkpoint blockade is favored.
Weaknesses
- Core biologic exclusivity has expired.
- The foundational composition protection is approaching or has passed the end of its commercial life in several jurisdictions.
- Method-of-use claims can be avoided through label design.
- Multiple checkpoint inhibitors provide alternative treatment options.
- Toxicity can reduce the eligible patient population.
The strongest continuing protection is likely to arise from the combination franchise, indication-specific claims and manufacturing know-how rather than from a single broad composition patent.
How does ipilimumab compare with nivolumab?
| Attribute |
Ipilimumab |
Nivolumab |
| Brand |
Yervoy |
Opdivo |
| Target |
CTLA-4 |
PD-1 |
| First U.S. approval |
2011 |
2014 |
| Main role |
Combination and selected monotherapy |
Broad monotherapy and combination use |
| Toxicity |
Generally higher immune-related toxicity |
Generally lower than CTLA-4 blockade |
| Commercial position |
Mature, approximately $2 billion product |
Much larger Bristol Myers Squibb franchise |
| Strategic value |
Enables dual-checkpoint regimens |
Core anchor of oncology portfolio |
Nivolumab has greater standalone commercial scale, but ipilimumab increases the clinical and commercial differentiation of the Opdivo franchise. The two products are economically linked even though their patent and regulatory positions differ.
What is the financial outlook for ipilimumab?
The base-case outlook is stable-to-declining revenue rather than renewed high growth.
Base-case trajectory
| Period |
Expected market dynamic |
| 2024-2025 |
Stable demand from approved combinations and global oncology use |
| 2026-2027 |
Greater patent-related pressure and possible early biosimilar launches |
| 2028 onward |
Gradual price erosion and volume migration, depending on biosimilar competition |
Revenue could remain resilient if Bristol Myers Squibb expands dual-checkpoint therapy into additional tumors or secures new dosing and combination data. Decline would accelerate if biosimilars enter multiple major markets and payers impose substitution or preferred-product policies.
The larger financial exposure is the Opdivo-Yervoy regimen. Even if Yervoy revenue falls, Bristol Myers Squibb may preserve part of the economic value through Opdivo demand, combination contracting and portfolio-level oncology agreements.
What licensing deals supported ipilimumab?
Medarex developed the antibody technology before Bristol Myers Squibb acquired Medarex for approximately $2.4 billion in 2009. The transaction gave Bristol Myers Squibb control of ipilimumab and other Medarex immuno-oncology assets.[6]
The key commercial arrangement was therefore an acquisition rather than a later out-licensing transaction. The deal preceded Yervoy’s 2011 FDA approval and transferred the technology, development program and related intellectual property into Bristol Myers Squibb.
What generic launch scenarios exist for ipilimumab?
Three scenarios are commercially plausible:
Delayed biosimilar entry
Patent disputes, manufacturing complexity or limited reimbursement incentives delay entry until the late 2020s. Yervoy retains premium pricing but faces contracting pressure.
One or two biosimilar entrants
A limited number of suppliers enter with moderate discounts. Hospital systems adopt biosimilars selectively, while Bristol Myers Squibb protects volume through contracting and combination support.
Broad biosimilar competition
Multiple manufacturers enter major markets. Payers favor lower-cost products, resulting in price erosion and declining Yervoy volume. Bristol Myers Squibb’s remaining defense rests on clinical familiarity, supply reliability and combination-regimen contracting.
Key Takeaways
- Yervoy generated approximately $2.1 billion in global revenue in 2023.
- Ipilimumab’s commercial value is greater in combination with nivolumab than as a standalone drug.
- U.S. biologic exclusivity ended in March 2023.
- Patent protection and biosimilar litigation remain relevant after regulatory exclusivity expiration.
- The main competitive threat is gradual biosimilar erosion combined with substitution by PD-1 or PD-L1 therapies.
- Bristol Myers Squibb’s 2009 acquisition of Medarex secured the core ipilimumab technology.
- The product’s most durable defenses are combination use, manufacturing complexity, clinical evidence and oncology contracting.
- Revenue is likely to remain resilient in the near term but trend downward as biosimilar competition develops.
FAQs
Is ipilimumab still commercially important after biologic exclusivity expired?
Yes. Yervoy remains important because it is part of high-value nivolumab combination regimens and has approvals across multiple cancer types.
Can a biosimilar replace Yervoy automatically?
Not necessarily. Automatic substitution depends on FDA interchangeability status and applicable state law. Hospital and payer formularies may drive adoption before pharmacy-level substitution becomes relevant.
Does ipilimumab have a generic equivalent?
No conventional generic equivalent exists. Ipilimumab is a biologic, so competition would come through biosimilars or interchangeable biosimilars.
Which company owns ipilimumab?
Bristol Myers Squibb owns and markets ipilimumab as Yervoy after acquiring Medarex in 2009.
Is ipilimumab more vulnerable than nivolumab to competition?
Yes. Ipilimumab has a smaller standalone market, higher toxicity and fewer monotherapy applications. Its strongest defense is its role in combination regimens with nivolumab.
References
- U.S. Food and Drug Administration. (2024). Yervoy (ipilimumab) prescribing information. https://www.accessdata.fda.gov
- Bristol Myers Squibb. (2024). 2023 annual report. https://www.bms.com/investors/annual-reports.html
- U.S. Food and Drug Administration. (2024). Biologics price competition and innovation act. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla
- U.S. Patent and Trademark Office. (2006). U.S. Patent No. 6,984,720, Human CTLA-4 antibodies. https://patents.google.com/patent/US6984720
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
- Bristol Myers Squibb. (2009). Bristol-Myers Squibb completes acquisition of Medarex. https://www.bms.com/media/press-releases.html
